Sheldon Krimsky

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2704994/publications.pdf

Version: 2024-02-01

393982 288905 62 1,622 19 40 citations g-index h-index papers 67 67 67 1069 docs citations times ranked citing authors all docs

| # | Article | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Financial Ties between DSM-IV Panel Members and the Pharmaceutical Industry. Psychotherapy and Psychosomatics, 2006, 75, 154-160. | 4.0 | 196 |
| 2 | Conflict of interest policies in science and medical journals: Editorial practices and author disclosures. Science and Engineering Ethics, 2001, 7, 205-218. | 1.7 | 177 |
| 3 | A Comparison of DSM-IV and DSM-5 Panel Members' Financial Associations with Industry: A Pernicious Problem Persists. PLoS Medicine, 2012, 9, e1001190. | 3.9 | 150 |
| 4 | Conflicts of Interest and Disclosure in the American Psychiatric Association's Clinical Practice Guidelines. Psychotherapy and Psychosomatics, 2009, 78, 228-232. | 4.0 | 116 |
| 5 | The Weight of Scientific Evidence in Policy and Law. American Journal of Public Health, 2005, 95, S129-S136. | 1.5 | 95 |
| 6 | Evaluating Risk Communication: Narrative vs. Technical Presentations of Information About Radon. Risk Analysis, 1992, 12, 27-35. | 1.5 | 82 |
| 7 | Financial interests of authors in scientific journals: A pilot study of 14 publications. Science and Engineering Ethics, 1996, 2, 395-410. | 1.7 | 80 |
| 8 | Financial Interest and Its Disclosure in Scientific Publications. JAMA - Journal of the American Medical Association, 1998, 280, 225. | 3.8 | 72 |
| 9 | The unsteady state and inertia of chemical regulation under the US Toxic Substances Control Act. PLoS Biology, 2017, 15, e2002404. | 2.6 | 55 |
| 10 | Ten ways in which He Jiankui violated ethics. Nature Biotechnology, 2019, 37, 19-20. | 9.4 | 47 |
| 11 | Conflicts of Interest in Approvals of Additives to Food Determined to Be Generally Recognized as Safe. JAMA Internal Medicine, 2013, 173, 2032. | 2.6 | 44 |
| 12 | Conflict of Interest and Cost-effectiveness Analysis. JAMA - Journal of the American Medical Association, 1999, 282, 1474. | 3.8 | 43 |
| 13 | Tripartite Conflicts of Interest and High Stakes Patent Extensions in the DSM-5. Psychotherapy and Psychosomatics, 2014, 83, 106-113. | 4.0 | 39 |
| 14 | Developing Unbiased Diagnostic and Treatment Guidelines in Psychiatry. New England Journal of Medicine, 2009, 360, 2035-2036. | 13.9 | 36 |
| 15 | Journal Policies on Conflict of Interest: If this Is the Therapy, What's the Disease?. Psychotherapy and Psychosomatics, 2001, 70, 115-117. | 4.0 | 31 |
| 16 | EPISTEMIC CONSIDERATIONS ON THE VALUE OF FOLK-WISDOM IN SCIENCE AND TECHNOLOGY. Review of Policy Research, 1984, 3, 246-263. | 2.8 | 30 |
| 17 | From Asilomar to industrial biotechnology: Risks, reductionism and regulation. Science As Culture, 2005, 14, 309-323. | 2.4 | 27 |
| 18 | Advice Without Dissent. Science, 2002, 298, 703-703. | 6.0 | 25 |

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Roundup litigation discovery documents: implications for public health and journal ethics. Journal of Public Health Policy, 2018, 39, 318-326. | 1.0 | 24 |
| 20 | An Epistemological Inquiry into the Endocrine Disruptor Thesis. Annals of the New York Academy of Sciences, 2006, 948, 130-142. | 1.8 | 22 |
| 21 | Commentary: Fraudulent Human Embryonic Stem Cell Research in South Korea: Lessons Learned. Accountability in Research, 2006, 13, 101-109. | 1.6 | 21 |
| 22 | From <i>caveat emptor</i> to <i>caveat venditor</i> : time to stop the influence of money on practice guideline development. Journal of Evaluation in Clinical Practice, 2014, 20, 809-812. | 0.9 | 19 |
| 23 | Conflict of Interest Policies and Industry Relationships of Guideline Development Group Members: A Cross-Sectional Study of Clinical Practice Guidelines for Depression. Accountability in Research, 2017, 24, 99-115. | 1.6 | 19 |
| 24 | Regulatory Oversight of Genetically Engineered Microorganisms: Has Regulation Inhibited Innovation?. Environmental Management, 1997, 21, 571-586. | 1.2 | 16 |
| 25 | The short life of a race drug. Lancet, The, 2012, 379, 114-115. | 6.3 | 16 |
| 26 | Human Gene Therapy: Must We Know Where to Stop Before We Start?. Human Gene Therapy, 1990, 1, 171-173. | 1.4 | 13 |
| 27 | Conflicts of interest among committee members in the National Academies' genetically engineered crop study. PLoS ONE, 2017, 12, e0172317. | 1.1 | 12 |
| 28 | Standardized Microcosms in Microbial Risk Assessment. BioScience, 1995, 45, 590-599. | 2.2 | 11 |
| 29 | Beyond Technocracy: New Routes for Citizen Involvement in Social Risk Assessment. Nonprofit and Voluntary Sector Quarterly, 1982, 11, 8-23. | 0.2 | 9 |
| 30 | Testing Pesticides in Humans. JAMA - Journal of the American Medical Association, 2007, 297, 2405. | 3.8 | 9 |
| 31 | Can Glyphosate-Based Herbicides Contribute to Sustainable Agriculture?. Sustainability, 2021, 13, 2337. | 1.6 | 9 |
| 32 | An Analysis of Toxicology and Medical Journal Conflict-of-Interest Polices. Accountability in Research, 2009, 16, 235-253. | 1.6 | 8 |
| 33 | Editorial policies on financial disclosure. Nature Neuroscience, 2003, 6, 1001-1001. | 7.1 | 7 |
| 34 | Using Dialogues to Explore Genetics, Ancestry, and Race. American Biology Teacher, 2017, 79, 525-537. | 0.1 | 6 |
| 35 | Breaking the germline barrier in a moral vacuum. Accountability in Research, 2019, 26, 351-368. | 1.6 | 6 |
| 36 | Risk assessment and regulation of bioengineered food products. International Journal of Biotechnology, 2000, 2, 231. | 1.2 | 5 |

| # | Article | IF | Citations |
|----|---|-------------|-----------|
| 37 | The Moral Choices on CRISPR Babies. American Journal of Bioethics, 2019, 19, 15-16. | 0.5 | 5 |
| 38 | Emergence of a Scientific and Commercial Research and Development Infrastructure for Human Gene Therapy. Human Gene Therapy, 2005, 16, 169-177. | 1.4 | 4 |
| 39 | Introduction to Special Issue of Accountability in Research on Conflict of Interest in Science. Accountability in Research, 2004, 11, 79-81. | 1.6 | 4 |
| 40 | A citizen court in the recombinant DNA debate. Bulletin of the Atomic Scientists, 1978, 34, 37-43. | 0.2 | 3 |
| 41 | Endocrine Disruptorsâ€"A Controversy in Science and Policy: Session III Summary and Research Needs. NeuroToxicology, 2001, 22, 557-558. | 1.4 | 3 |
| 42 | The Dilemma in Regulating Drug Advertising: Propositional Versus Nonpropositional Content. American Journal of Bioethics, 2013, 13, 16-17. | 0.5 | 3 |
| 43 | If the "Physician Payments Sunshine Act―ls a Solution, What Is the Problem?. American Journal of Bioethics, 2017, 17, 29-30. | 0.5 | 3 |
| 44 | Glyphosate Toxicology. Health Information Systems and the Advancement of Medical Practice in Developing Countries, 2019, , 343-356. | 0.1 | 3 |
| 45 | Pure Science and Impure Scientists: Dilemmas for Public Policy. Politics and the Life Sciences, 1984, 3, 49-51. | 0.5 | 2 |
| 46 | Commentary on "the politics of certainty―(C. A. Rubino). Science and Engineering Ethics, 2000, 6, 509-510. | 1.7 | 2 |
| 47 | Implicit precaution, scientific inference, and indirect evidence: the basis for the US Environmental Protection Agency's regulation of genetically modified crops. New Genetics and Society, 2003, 22, 159-175. | 0.7 | 2 |
| 48 | Crossing the Germline Barrier: The Three Genome Baby. Ethics in Biology, Engineering & Medicine, 2015, 6, 237-261. | 0.1 | 2 |
| 49 | Glyphosate-Based Herbicides and Public Health: Making Sense of the Science. Journal of Agricultural and Environmental Ethics, 2022, 35, 1. | 0.9 | 2 |
| 50 | The University: Marketing Theories, Not Toothpaste. Environment, 1982, 24, 46-48. | 0.8 | 1 |
| 51 | The Gene Wars: Science, Politics, and the Human Genome - Robert Cook-Deegan. New York: W. W. Norton, 1994, 416pp. US\$25.00 cloth. ISBN 0-393-03572-7. US\$14.95 paper. ISBN 0-393-31399-9. W. W. Norton 500 Fifth Ave., New York, NY 10110, USA Politics and the Life Sciences, 1996, 15, 130-131. | 1,0.5 | 1 |
| 52 | Beware of gifts that come at too great a cost. Nature, 2011, 474, 129-129. | 13.7 | 1 |
| 53 | BiDil: alive and kicking – Author' reply. Lancet, The, 2012, 379, 1876-1877. | 6. 3 | 1 |
| 54 | Sugar Industry Science and Heart Disease. Accountability in Research, 2017, 24, 124-125. | 1.6 | 1 |

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | A Neoliberal Economics of Science. American Scientist, 2011, 99, 330. | 0.1 | 1 |
| 56 | An experiment in environmental education for citizen advocates. Alternative Higher Education, 1978, 2, 210-222. | 0.1 | 0 |
| 57 | Science, Biopolitics and Risk: Margins of Uncertainty. Politics and the Life Sciences, 1989, 7, 140-142. | 0.5 | О |
| 58 | Agricultural Bioethics: Implications of Agricultural Biotechnology. 1990. Edited by Steven M. Gendel, A. David Kline, D. Michael Warren, and Faye Yates. Iowa State University Press, Ames, Iowa, xxiv, 357 pp. \$34.95, cloth Renewable Agriculture and Food Systems, 1991, 6, 42-43. | 0.6 | 0 |
| 59 | Commentary: Corporate philanthropy and conflicts of interest in public health. Journal of Public Health Policy, 2013, 34, 137-139. | 1.0 | 0 |
| 60 | Genetic Causation. Advances in Child Development and Behavior, 2013, 44, 307-323. | 0.7 | 0 |
| 61 | Disguised Academic Plagiarism. A typology and case studies for researchers and editors. Research ethics forum 8. Accountability in Research, 2021, 28, 44-46. | 1.6 | 0 |
| 62 | Book review of "Bioethics in Action―Cambridge University Press. Accountability in Research, 2022, 29, 1-3. | 1.6 | 0 |